Photon Absorption characteristics of some selected Enzyme Inhibitors used in Cancer Research in the Energy range 1 keV-100 GeV
Journal of Radiology and Oncology · 2017
DOI: 10.29328/journal.jro.1001009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Radiology and Oncology, 2017. Verfasst von Mustafa Recep Kaçal und 2 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The absorption parameters such as total mass attenuation coefficients, molecular, atomic, and electronic cross sections, effective atomic numbers and electron densities were calculated for some selected enzyme inhibitors in the photon energy range from 1 keV up to 100 GeV. The changes in the absorption parameters were interpreted with the photoelectric effect, Compton scattering and pair production processes. It is observed that the 2-Imino-1-imidazolidineacetic acid enzyme inhibitor has more radiation shielding feature when compared to other chosen enzyme inhibitors. The present investigation is anticipated to be useful for researchers studying with radiation in several fields and cancer researchers.
Zitieren
APA
Kaçal, M. R., Karataş, H. A., & Akman, F. (2017). Photon Absorption characteristics of some selected Enzyme Inhibitors used in Cancer Research in the Energy range 1 keV-100 GeV. Journal of Radiology and Oncology. https://doi.org/10.29328/journal.jro.1001009
Vancouver
Kaçal MR, Karataş HA, Akman F. Photon Absorption characteristics of some selected Enzyme Inhibitors used in Cancer Research in the Energy range 1 keV-100 GeV. Journal of Radiology and Oncology. 2017. doi:10.29328/journal.jro.1001009
BibTeX
@article{Kaal2017,
author = {Kaçal, Mustafa Recep and Karataş, Hüseyin Ali and Akman, Ferdi},
title = {Photon Absorption characteristics of some selected Enzyme Inhibitors used in Cancer Research in the Energy range 1 keV-100 GeV},
journal = {Journal of Radiology and Oncology},
year = {2017},
doi = {10.29328/journal.jro.1001009}
}
EUVIMED